Podcast appearances and mentions of Johnson Johnson

CHROs, your role has never been more vital or more complex. AI, shifting politics, hybrid work, and evolving employee expectations, have taken the front seat in today's world of work. The future says you're no longer just managing HR, you're redefining the workplace itself. That's exactly why I launched Future of Work Leaders, a supportive global community built specifically for CHROs who are ready to move beyond traditional HR and are committed to building future-ready organizations.  In this episode, I share highlights from our very first 2025 gathering, where CHROs from some of the world's most respected brands came together to discuss the real challenges and opportunities shaping the future of work. I'm taking you behind the scenes of our inaugural Future of Work Leaders CHRO event, hosted at the Neiman Marcus Innovation Hub in Dallas. We brought together 40 CHROs from organizations like Johnson & Johnson, Northrop Grumman, Tractor Supply, Amway, and others to have deep, honest conversations about what's really driving change today. Topics like the evolving role of DEI, AI integration, hybrid work models, culture transformation, and even the political climate's impact on work. ________________ Start your day with the world's top leaders by joining thousands of others at Great Leadership on Substack. Just enter your email: ⁠⁠https://greatleadership.substack.com/

Debbie Reynolds, Chief Data Privacy Officer and host of “The Data Diva Talks Privacy” podcast, discusses the challenges parents face in protecting their children online, and simple habits users can adopt to take back control of their privacy. She also discusses the growing recognition among companies that excessive data collection poses significant risks. Key Takeaways:  How consumer expectations for data are privacy changing The asymmetrical relationship between consumers and companies regarding data privacy How companies can scale a human‑centric approach to privacy The importance of decentralization in future data management Guest Bio: Debbie Reynolds—aka “The Data Diva”—is a globally recognized technologist, thought leader, and advisor in data privacy and emerging technology. With over 20 years of experience, she has delivered keynote talks for major organizations like Coca-Cola, Johnson & Johnson, PayPal, TikTok, and Uber. Her insights have been featured in leading media outlets, including The New York Times, Forbes, Bloomberg, and Wired. Debbie hosts the #1 global award-winning podcast, “The Data Diva Talks Privacy,” which reaches listeners in over 120 countries. Identity Review has named her one of the Global Top Eight Privacy Experts, and the European Risk Policy Institute has named her a Top 30 CyberRisk Communicator. She also chairs the IEEE Cyber Security Committee for the Next Generation Connectivity Systems Privacy Labeling Project. ---------------------------------------------------------------------------------------- About this Show: The Brave Technologist is here to shed light on the opportunities and challenges of emerging tech. To make it digestible, less scary, and more approachable for all! Join us as we embark on a mission to demystify artificial intelligence, challenge the status quo, and empower everyday people to embrace the digital revolution. Whether you're a tech enthusiast, a curious mind, or an industry professional, this podcast invites you to join the conversation and explore the future of AI together. The Brave Technologist Podcast is hosted by Luke Mulks, VP Business Operations at Brave Software—makers of the privacy-respecting Brave browser and Search engine, and now powering AI everywhere with the Brave Search API. Music by: Ari Dvorin Produced by: Sam Laliberte

This episode covers: Cardiology This Week: A concise summary of recent studies The role of cardiac magnetic resonance in myocardial disease Air pollution and heart disease Statistics Made Easy: Quasi-experimental study designs Host: Rick Grobbee Guests: Carlos Aguiar, Steffen Petersen, Mark Miller Want to watch that episode? Go to: https://esc365.escardio.org/event/1806 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Mark Miller have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Steffen Petersen Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1806?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CBJ865. CME/AAPA/IPCE credit will be available until May 27, 2026.Personalizing Prostate Cancer Care: Real-World Approaches for the Community Urology Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CBJ865. CME/AAPA/IPCE credit will be available until May 27, 2026.Personalizing Prostate Cancer Care: Real-World Approaches for the Community Urology Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CBJ865. CME/AAPA/IPCE credit will be available until May 27, 2026.Personalizing Prostate Cancer Care: Real-World Approaches for the Community Urology Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CBJ865. CME/AAPA/IPCE credit will be available until May 27, 2026.Personalizing Prostate Cancer Care: Real-World Approaches for the Community Urology Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CBJ865. CME/AAPA/IPCE credit will be available until May 27, 2026.Personalizing Prostate Cancer Care: Real-World Approaches for the Community Urology Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CBJ865. CME/AAPA/IPCE credit will be available until May 27, 2026.Personalizing Prostate Cancer Care: Real-World Approaches for the Community Urology Practice In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Astellas and Pfizer, Inc., Bayer HealthCare Pharmaceuticals Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BYQ865. CME/MOC/AAPA/IPCE credit will be available until May 27, 2026.Putting Precision Into Practice for Bladder Cancer Treatment: Insights for Individualized Care Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BYQ865. CME/MOC/AAPA/IPCE credit will be available until May 27, 2026.Putting Precision Into Practice for Bladder Cancer Treatment: Insights for Individualized Care Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BYQ865. CME/MOC/AAPA/IPCE credit will be available until May 27, 2026.Putting Precision Into Practice for Bladder Cancer Treatment: Insights for Individualized Care Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BYQ865. CME/MOC/AAPA/IPCE credit will be available until May 27, 2026.Putting Precision Into Practice for Bladder Cancer Treatment: Insights for Individualized Care Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BYQ865. CME/MOC/AAPA/IPCE credit will be available until May 27, 2026.Putting Precision Into Practice for Bladder Cancer Treatment: Insights for Individualized Care Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BYQ865. CME/MOC/AAPA/IPCE credit will be available until May 27, 2026.Putting Precision Into Practice for Bladder Cancer Treatment: Insights for Individualized Care Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BYQ865. CME/MOC/AAPA/IPCE credit will be available until May 27, 2026.Putting Precision Into Practice for Bladder Cancer Treatment: Insights for Individualized Care Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/BYQ865. CME/MOC/AAPA/IPCE credit will be available until May 27, 2026.Putting Precision Into Practice for Bladder Cancer Treatment: Insights for Individualized Care Across the Disease Continuum In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).Disclosure information is available at the beginning of the video presentation.

This episode of PedsCases will give you an approach to congenital hemangiomas. By the end of this podcast, listeners will be able to 1) define hemangiomas and congenital hemangiomas, 2) explain the genetics and environmental factors associated with congenital hemangiomas, 3) describe the pathogenesis of congenital hemangiomas, 4) classify congenital hemangiomas, and 5) discuss the diagnosis, differential diagnosis, and management strategies for congenital hemangiomas. Today's episode was created by Emilie Wang, a medical student at the University of British Columbia, in collaboration with Dr. Joseph Lam, a pediatric dermatologist at BC Children's Hospital. An author of this podcast has financial support and has received speaker bursaries from Johnson & Johnson, Pierre-Fabre, Pfizer, Valeant, Sanofi Genzyme, Incyte, La Roche Posay Canada, Beiersdorf Canada and serves on advisory committees for Johnson & Johnson, Pierre-Fabre, Pfizer, Valeant, Sanofi Genzyme. They also serve as Associate Editor of Pediatric Dermatology Journal, and have been contributors to UpToDate, Medscape, BMJ Updates, and Eczema Society of Canada.  

John Green returns to the show to talk about tuberculosis — a disease that kills more than a million people a year. Steve has an idea for a new way to get treatment to those in need. SOURCES: John Green, best-selling author and YouTube creator. RESOURCES: Everything Is Tuberculosis: The History and Persistence of Our Deadliest Infection, by John Green (2025)."The Deadliest Infectious Disease Isn't a Science Problem. It's a Money Problem," by John Green (The Washington Post, 2024)."The Deadliest Infectious Disease of All Time," by John Green (Crash Course, 2024)."Barely Contained Rage: An Open Letter to Johnson & Johnson," by John Green (Vlogbrothers, 2023)."Designing Advance Market Commitments for New Vaccines," by Michael Kremer, Jonathan D. Levin, and Christopher M. Snyder (NBER, 2020)."Are CEOs Rewarded for Luck? The Ones Without Principals Are," by Marianne Bertrand and Sendhil Mullainathan (The Quarterly Journal of Economics, 2001)."A Further Communication on a Remedy for Tuberculosis," by Robert Koch (The Indian Medical Gazette, 1891). EXTRAS: "His Brilliant Videos Get Millions of Views. Why Don't They Make Money?" by People I (Mostly) Admire (2025)."Sendhil Mullainathan Thinks Messing Around Is the Best Use of Your Time (Update)," by People I (Mostly) Admire (2024)."John Green's Reluctant Rocket Ship Ride (Update)" by People I (Mostly) Admire (2024)."Rajiv Shah Never Wastes a Crisis," by People I (Mostly) Admire (2024)."'There's So Many Problems — Which Ones Can I Make a Difference On?'" by People I (Mostly) Admire (2022).The Anthropocene Reviewed: Essays on a Human-Centered Planet, by John Green (2021).The Anthropocene Reviewed (podcast).Nerdfighteria.TBFighters.

This episode covers: Cardiology This Week: A concise summary of recent studies Colchicine for secondary prevention An algorithmic approach to the workup of syncope Milestones: CIBIS II Host: Rick Grobbee Guests: Carlos Aguiar, Sanjit Jolly, Michele Brignole Want to watch that episode? Go to: https://esc365.escardio.org/event/1805 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Sanjit Jolly has declared to have potential conflicts of interest to report: grant support from Boston Scientific, honorarium from Boston Scientific, Shockwave, Abiomed, SIS, and Teleflex.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Michele Brignole Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1805?r  Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MBK865. CME/AAPA credit will be available until April 20, 2026.Starting With a Frontline “Four” in Multiple Myeloma: Case-Based Guidance for Achieving Durable Remissions With Innovative CD38 Antibody Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies) and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MBK865. CME/AAPA credit will be available until April 20, 2026.Starting With a Frontline “Four” in Multiple Myeloma: Case-Based Guidance for Achieving Durable Remissions With Innovative CD38 Antibody Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies) and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MBK865. CME/AAPA credit will be available until April 20, 2026.Starting With a Frontline “Four” in Multiple Myeloma: Case-Based Guidance for Achieving Durable Remissions With Innovative CD38 Antibody Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies) and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/MBK865. CME/AAPA credit will be available until April 20, 2026.Starting With a Frontline “Four” in Multiple Myeloma: Case-Based Guidance for Achieving Durable Remissions With Innovative CD38 Antibody Strategies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies) and Sanofi.Disclosure information is available at the beginning of the video presentation.

Scott Wapner and the Investment Committee debate the rebound in stocks as the S&P 500 heads for its longest winning streak in 20 years. The experts detail their latest portfolio moves. CNBC Senior Markets Commentator Michael Santoli joins from Omaha with a special Midday Word ahead of Berkshire Hathaway's annual shareholder meeting. Calls of the Day include AutoZone, Roblox, Eli Lilly, Johnson & Johnson, and Quanta Services. NBC Sports host Mike Tirico is live in Churchill Downs ahead of the 151st Kentucky Derby. The Setup is on Ferrari, Zoetis, Elanco Animal Health.Investment Committee Disclosures

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A new Austrailian study aims to prevent type 1, the new twiist pump will integrate with Eversnse CGM as well as Libre, diabetes deaths are down in the US, Dexcom U is looking for college athletes, and more! Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX A world-first human trial of a drug designed to treat the underlying cause of type 1 diabetes has begun in Australia. University of Queensland researcher Ranjeny Thomas said the experimental drug — dubbed ASITI-201 — was designed to retrain the immune system so it no longer attacks the insulin-producing pancreatic cells, known as beta cells. The drug, given as an injection under the skin, combines fragments of a protein found in the beta cells of people with type 1 diabetes and vitamin D to calm the immune response. She said if effective, the drug would initially be given to patients with type 1 diabetes as soon as possible after diagnosis to preserve remaining pancreatic cells and reduce the amount of insulin needed. But eventually, if screening programs can be developed to pick up people at risk of developing type 1 diabetes, it may be possible to "prevent the progression of the disease altogether". The first in-human trial of 36 participants will test the safety of the drug, but blood tests will also determine the impact of the therapy on a patient's immune system and glucose tolerance. https://www.abc.net.au/news/2025-04-29/type-1-diabetes-drug-trial-auto-immune-disease-science/105223022 XX   Diabetes deaths in the U.S. have fallen to some of the lowest rates in years, according to new preliminary figures published by the Centers for Disease Control and Prevention, reversing a surge in mortality that was seen during the COVID-19 pandemic.   There were 26.4 deaths per 100,000 people from diabetes, according to early death certificate data for the third quarter of 2024 published this month by the CDC's National Center for Health Statistics.   Death rates from diabetes peaked in 2021, according to CDC figures, at 31.1 deaths per 100,000 people for that year. Diabetes was the eighth leading cause of death in 2021. The CDC says the link between COVID-19 and diabetes may be to blame for that increase.   "Data show an increase in mortality rates for all people during the COVID-19 pandemic, and research shows that people with underlying conditions, including diabetes, are more likely to become very sick from COVID-19 and have a higher risk of hospitalization and death," Christopher Holliday, head of the CDC's Division of Diabetes Translation, told CBS News in a statement.   Holliday added that research shows the pandemic may also have made it harder for Americans to properly manage the disease, ranging from interruptions to physical activity to disruptions to routine medical care diagnosing and treating the disease.   https://www.cbsnews.com/news/diabetes-deaths-lowest-levels-years-early-cdc-figures/ XX Big news for the Eversense CGM – they have their first pump partner. Sequel Med Tech says the twist pump will integrate with Senseonics Eversense 365 continuous glucose monitor (CGM). This collaboration would make twiist the first AID system compatible with Eversense 365, the world's first and only one-year CGM. Sequel and Senseonics say they have already started their work to integrate the latest-generation, 365-day implantable sensor with twiist. They expect to make the integrated offering available in the third quarter of this year. This marks the second CGM integration for Sequel, which partnered with Abbott and its FreeStyle Libre platform earlier this year. This week we also got a peek at the packaging and delivery of the twist as the first people posted about wearing it. We'll follow up and learn more about this newest insulin pump in the us. Senseonics, meanwhile, brought the first year-long CGM to market last year, launching Eversense 365 with its global distribution partner, Ascensia Diabetes Care, in October 2024. The system also received clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems. https://www.drugdeliverybusiness.com/sequel-senseonics-integrate-cgm-insulin-pump/ XX Medtronic has announced the U.S. Food and Drug Administration (FDA) approval for the Simplera Sync sensor for use with the MiniMed 780G system. With this approval, the MiniMed 780G system now offers more flexibility for users of the company's most advanced insulin delivery system featuring Meal Detection technology with both the Guardian 4 sensor and Simplera Sync sensor.   The Simplera Sync is a disposable, all-in-one sensor that requires no fingersticks with SmartGuard or overtape and features a simple, two-step insertion process. It is the company's newest addition to its CGM portfolio, which expands options and provides greater flexibility for users.   The MiniMed 780G system's adaptive algorithm automatically anticipates, adjusts, and corrects glucose levels every 5 minutes, 24/7 – working around the clock so users can focus on what matters. It's the only system featuring Meal Detection technology, which detects rising sugar levels and delivers more insulin as needed to help users keep glucose levels in range more often – even when users occasionally forget to dose insulin for snacks or meals or underestimate their carbs.   The system uses a “treat to target” approach and flexible glucose targets as low as 100 mg/dL, which, combined with its adaptive algorithm allows it to more closely mirror the glucose levels of someone not living with diabetes.   Real-world data of the system shows global users consistently achieve time in range above international targets of 70% when using optimal settings (active insulin time of two hours and 100 mg/dL target glucose). It is also the only system that works with the world's only infusion set that lasts up to 7 days so that users only have to change their infusion set once per week and can experience 96% fewer injections compared to multiple daily injections.   “We're committed to driving innovation that makes life easier for those living with diabetes so they can forget about their diabetes as much as possible throughout the day,” said Que Dallara, EVP and president of Medtronic Diabetes. “Our MiniMed 780G system delivers advanced diabetes technology for so many around the world, and we're excited to continue evolving this experience with expanded CGM options —including our Simplera Sync sensor, which we look forward to bringing to people living with diabetes in the U.S.”   A limited launch of the Simplera Sync sensor will begin in the U.S. in the fall of 2025. Today, the MiniMed 780G system can be used with the Guardian 4 sensor.   Like this:https://med-techinsights.com/2025/04/29/simplera-sync-sensor-for-minimed-780g-now-fda-approved/ XX Front office changes at Insulet.. The former head of Johnson & Johnson's worldwide medtech business, Ashley McEvoy will take over as president and CEO from Jim Hollingshead, who has led Insulet since 2022. In its announcement of the leadership change, Insulet said that Hollingshead and the company mutually agreed to part ways, effective immediately. McEvoy served as worldwide medtech chairman at J&J from 2018 until her departure in late 2023, the culmination of nearly 30 years at the company and several executive roles—including president of its Ethicon division and group chairman of vision and diabetes care. Since then, she has also served as a board member at Procter & Gamble. https://www.fiercebiotech.com/medtech/insulet-taps-former-jj-medtech-head-ashley-mcevoy-be-ceo XX New free mobile game launched this week to make type 1 diabetes onboarding faster easier and less overwhelming. It's called Level One.. created by Level Ex (Powered by Relevate Health), the studio behind award-winning medical games for medical professionals. Level Ex CEO Sam Glassenberg created the game after a – quote  - brutal onboarding experience when his daughter was diagnosed five years ago He says  It took a year to understand how to manage this disease. So we fixed it. We built a game that can train your brain to do it in a matter of hours." The game is launching in partnership with leading diabetes organizations Beyond Type 1 and Breakthrough T1D Play, who are integrating Level One into their outreach and educational campaigns to support newly diagnosed families worldwide. Download Level One on the App Store: https://apps.apple.com/us/app/level-one-a-diabetes-game/id6739605694 Learn more: https://playlevelone.com   https://www.prnewswire.com/news-releases/level-ex-launches-level-one-a-free-mobile-game-to-redefine-type-1-diabetes-onboarding-302440929.html XX   Collagen is widely recognized for its role in maintaining healthy skin, but its importance extends far beyond that. As the most abundant protein in the human body, collagen provides essential structure and support to nearly all tissues and organs.   Now, researchers at Carnegie Mellon's Feinberg Lab have made a major breakthrough using their novel Freeform Reversible Embedding of Suspended Hydrogels (FRESH) 3D bioprinting technique. This method enables the precise printing of soft, living cells and tissues. Leveraging this technology, the team successfully created the first-ever microphysiologic system, also known as a tissue model, constructed entirely from collagen. This advancement opens new possibilities for studying disease and engineering tissue therapies, including potential treatments for conditions like Type 1 diabetes.   Traditionally, small-scale models of human tissue, referred to as microfluidics, organ-on-chip devices, or microphysiologic systems, have been fabricated using synthetic materials such as silicone rubber or plastics. These materials were necessary due to limitations in earlier manufacturing techniques. However, because they are not biologically native, they fail to fully replicate natural tissue environments, restricting their effectiveness in biomedical research and therapeutic development.   “Now, we can build microfluidic systems in the Petri dish entirely out of collagen, cells, and other proteins, with unprecedented structural resolution and fidelity,” explained Adam Feinberg, a professor of biomedical engineering and materials science & engineering at Carnegie Mellon University. “Most importantly, these models are fully biologic, which means cells function better.”   Building Complex Tissues with FRESH Bioprinting In new research published in Science Advances, the group demonstrates the use of this FRESH bioprinting advancement, building more complex vascularized tissues out of fully biologic materials, to create a pancreatic-like tissue that could potentially be used in the future to treat Type 1 diabetes. This advancement in FRESH bioprinting builds on the team's earlier work published in Science, by improving the resolution and quality to create fluidic channels that are like blood vessels down to about 100-micron diameter.   “There were several key technical developments to the FRESH printing technology that enabled this work,” described Daniel Shiwarski, assistant professor of bioengineering at the University of Pittsburgh and prior postdoctoral fellow in the Feinberg lab. “By implementing a single-step bioprinting fabrication process, we manufactured collagen-based perfusable CHIPS in a wide range of designs that exceed the resolution and printed fidelity of any other known bioprinting approach to date. Further, when combined with multi-material 3D bioprinting of ECM proteins, growth factors, and cell-laden bioinks and integration into a custom bioreactor platform, we were able to create a centimeter-scale pancreatic-like tissue construct capable of producing glucose-stimulated insulin release exceeding current organoid based approaches.” https://scitechdaily.com/scientists-bioprint-living-tissues-that-could-revolutionize-diabetes-treatment/ XX Another study showing the blood sugar benefit of walking after a meal. Skeletal muscle plays a central role in glucose uptake. Exercise stimulates glucose transport into muscle cells through insulin-independent pathways, notably through the action of glucose transporter type 4 (GLUT-4), which is responsible for transporting glucose from blood to skeletal muscles.4 This means that even without a robust insulin response, physical activity can facilitate glucose clearance from the bloodstream. These effects also occur without requiring high-intensity exercise, making postprandial walking accessible to a broad range of individuals, including those with limited exercise tolerance. multiple studies show that starting activity within 30 minutes after a meal is optimal. https://www.news-medical.net/health/Walking-After-Meals-Small-Habit-Big-Metabolic-Gains.aspx XX Dexcom brings back Dexcom U for a 4th years. This is a name, image and license program for college athletes with diabetes and includes a nationwide open call for passionate and inspiring college athletes to join its roster. Now through May 23, athletes, coaches, friends and family members can nominate candidates through an online submission. Those selected, along with the eight returning athletes from last year, will be invited to attend the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. https://www.hmenews.com/article/dexcom-u-returns-for-fourth-season

The Rich Zeoli Show- Hour 3: 5:00pm- On Wednesday, President Donald Trump held a press conference announcing financial investments in America from companies like Amazon, IBM, Nvidia, Johnson & Johnson, and Eli Lilly & Company. In total, the Trump Administration estimates that the investments in “America's future” amount to over $5 trillion in his first 100 days in office—with the creation of “more than 451,000 new jobs.” 5:30pm- “Shark Tank” star Kevin O'Leary hilariously explained that socialist Rep. Alexandria Ocasio Cortez is really a capitalist—pointing out her “Tax the Rich” t-shirts which she makes an “82% margin on.”

The Rich Zeoli Show- Full Show (04/30/2025): 3:05pm- Last night, President Donald Trump celebrated the first 100 Days of his second term in office with a rally in Michigan—highlighting his successes and calling out Democrats who are already seeking to impeach him. Tonight, former Vice President Kamala Harris is expected to deliver her own address—her first major speech since losing the 2024 presidential election. According to reports, she is expected to “call out” President Trump and his administration. 3:30pm- On Monday, Rich, Matt, and Rich's son Patrick visited the White House to celebrate the first 100 days of President Trump's second term in office—as well as the Super Bowl Champion Philadelphia Eagles. While the visit was enjoyable, why didn't Matt stop for food on the way home??? 3:40pm- On Tuesday night, President Donald Trump sat down for an interview with Terry Moran of ABC News. During the conversation, Trump defended his decision to revoke Joe Biden's security clearances. He also said he considers securing the border his greatest accomplishment thus far. 3:50pm- World War II Bomb in Cape May? According to a report from Fox 29, an unexploded World War II ordinance was discovered during low tide earlier this week—forcing a bomb squad to deactivate the device. 4:05pm- During Wednesday's cabinet meeting, Treasury Secretary Scott Bessent said the rare earth mineral deal with Ukraine “is ready to sign”—and although Ukraine recently made “some last-minute changes” it could be agreed upon as soon as “this afternoon.” Meanwhile, Secretary of State Marco Rubia reacted to Kilmar Abrego Garcia's deportation to El Salvador. He noted that “the conduct of our foreign policy belongs to the President of the United States and the Executive Branch—not some judge.” 4:40pm- Health and Human Services Secretary Robert Kennedy Jr. discussed his efforts to “make America healthy again” during Wednesday's cabinet meeting with President Donald Trump. Sec. Kennedy specifically touted his department's recently announced “ban on nine petroleum-based synthetic food dyes.” 5:00pm- On Wednesday, President Donald Trump held a press conference announcing financial investments in America from companies like Amazon, IBM, Nvidia, Johnson & Johnson, and Eli Lilly & Company. In total, the Trump Administration estimates that the investments in “America's future” amount to over $5 trillion in his first 100 days in office—with the creation of “more than 451,000 new jobs.” 5:30pm- “Shark Tank” star Kevin O'Leary hilariously explained that socialist Rep. Alexandria Ocasio Cortez is really a capitalist—pointing out her “Tax the Rich” t-shirts which she makes an “82% margin on.” 6:05pm- Daniel Turner—Founder and Executive Director of Power the Future—joins The Rich Zeoli Show to discuss his latest op-ed for The New York Post, “How Trump turned around a Biden energy policy based on hand waves and lies.” You can read the full article here: https://nypost.com/2025/04/28/opinion/how-trump-turned-around-a-biden-energy-policy-based-on-hand-waves-and-lies/. 6:30pm- During Wednesday's cabinet meeting, President Donald Trump thanked Elon Musk for his work at DOGE—as Musk begins to transition back to his work in the private sector. Plus, Governor Gavin Newsom claims he invented DOGE six years ago…but that California did it better than the Trump Administration. What the heck is he talking about!?

This episode covers: Cardiology This Week: A concise summary of recent studies Hypertension in the elderly The digital twin in cardiology Snapshots Host: Emer Joyce Guests: Carlos Aguiar, Gianfranco Parati, Nico Bruining, Joost Lumens Want to watch that episode? Go to: https://esc365.escardio.org/event/1804 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Nico Bruining, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Joost Lumens has declared to have potential conflicts of interest to report: research grants from Medtronic (all grants paid to institute, Maastricht University). Gianfranco Parati has declared to have potential conflicts of interest to report: honoraria for lectures by Omron, Merck, Viatris, Somnomedics. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guests: Joost Lumens and Nico Bruining Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1804?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.  Declarations of interests: Stephan Achenbach, Nico Bruining, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Joost Lumens has declared to have potential conflicts of interest to report: research grants from Medtronic (all grants paid to institute, Maastricht University). Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Are you a Chief Human Resource Officer trying to find a meaningful and affordable peer group that's NOT stuck in the past? I'm glad you found this episode because you're about to discover a CHRO community that's building the future of work as we speak. After speaking with over 100 CHROs for my book on employee experience, I kept hearing the same frustrations about existing groups with overpriced memberships, bloated conferences, constant sales pitches, outdated content, and a total lack of real value. So I decided to do something about it. In this episode, I'm pulling back the curtain on "Future of Work Leaders," a new community built for CHROs, by CHROs. It's an intimate group focused on one thing only: insight-rich conversations for forward-thinking CHROs like you. If you're a CHRO who's done playing by old rules and wants to connect with other future-ready leaders from companies like Johnson & Johnson, Northrop Grumman, Dow, Amway, and more, consider this your invite.   ________________ Start your day with the world's top leaders by joining thousands of others at Great Leadership on Substack. Just enter your email: ⁠⁠https://greatleadership.substack.com/

This week, Ivy Slater, host of Her Success Story, chats with her guest, Anna Villa-Bager. The two talk about the origins of Marble Jam's distinctive name, the strategic steps Anna took to build a robust nonprofit, and the comprehensive programs that Marble Jam offers, including various creative arts therapies and digital arts.  In this episode, we discuss: How the idea began with the creation of a children's television show named "Marble Jam," which was creatively inspired by character initials and led to a broader mission after personal experiences. Marble Jam's development and expansion from one signature program to a large facility with numerous creative arts programs and therapies. The power of building relationships played a crucial role in starting and growing the nonprofit organization. Stories of growth and development in participants through Marble Jam's programs, focusing on children and adults with special needs.  Resilience, flexibility, and the importance of surrounding oneself with knowledgeable individuals to make a difference in the community. The importance of purpose in nonprofit work and how it sustains and motivates staff and leadership within Marble Jam.   Anna Villa-Bager, Founder /President of Marble Jam  Anna's experience in the entertainment industry spans over twenty years in all aspects of entertainment, including corporate show production, from initial concept to completion, music and book development, costuming, casting, and choreography. In the large corporate arena, Anna co-developed and produced national and regional industrial shows for many companies, including Johnson & Johnson, Cooper Vision, and Becton Dickinson. She was a spokesperson and performer with Adidas USA for International Super Shows worldwide. Her portfolio includes an extensive theatrical performance career.   As an original cast member of Jerome Robbins Broadway, Anna performed and assisted Mr. Robbins in reconstructing dance pieces from notation and old film archives. Other performance credits include Broadway, International and National Tours, Regional and Children's Theatre, film and television.   With a foundation in dance and psychology, her tenure at MarbleJam has been dedicated to enriching lives through the arts. Leveraging her social networking, music, and theatre expertise, she fosters an environment where creativity meets advocacy, empowering children and adults alike. With a focus on strategic growth and community engagement at the organization's helm, she ensures the mission resonates and impacts widely.  The journey from an international and Broadway dancing career to the founder of a nonprofit organization illustrates a trajectory shaped by a commitment to artistic expression and social contribution. Her team's achievements, such as establishing specialized programs and securing vital resources, reflect a shared vision of accessibility and joy in the arts. This path reflects not just a career but her profound personal calling inspired by her family and the transformative power of art.   Anna graduated from the State University of New York at Brockport with a BS in dance with a focus on psychology. She is certified in nonprofit executive management and development and is a certified career planning counselor. Anna maintains all union affiliations with SAG-AFTRA and Actors Equity Association.  Website: https://marblejam.org/   Social Media Links: Anna Villa-Bager Links: LinkedIn: https://www.linkedin.com/in/anna-villa-bager-cne-cde-2369829/ Facebook: https://www.facebook.com/anna.villabager Instagram: https://www.instagram.com/avbager/?hl=en   MarbleJam Links:   Facebook: https://www.facebook.com/marblejamkids Instagram: https://www.instagram.com/marblejamkids/# YouTube: https://www.youtube.com/channel/UCn94l-kYie7OkvRCCxuwRUg Email: info@marblejam.org  

Over the past 2 decades, Gardiner Harris has been covering and collecting data on Johnson&Johnson. Now, as an independent and award-winning investigative journalist, he releases the fruits of 2 decades of research, interviews, analysis and findings in No More Tears: The dark secrets of Johnson & Johnson exposed. In this show we explore: The collapse of a strong public health frameworkThe infiltration of industry into public serviceThe specific ways in which Johnson&Johnson has caused millions harm over decades across a number of their products. The opioid crisis, hip replacements, vaginal mesh, anemia drug EPO in cancer patients and antipsycholotics in aged care and more… The way J&J can stay afloat despite all of the damages and legal feesWhat hope we have of restoring faith in health care? What you and I can do to ensure at the grass roots we are building a better system.It's a doozy, I'm not going to lie, but it's important work and Gardiner has done some extraordinary work to bring this story to light. Alexx StuartYour Host, Low Tox Life PodcastWant to learn more about this week's guest? Website: gardinerharris.com The book: https://bit.ly/4kkKc8p Thank you to this month's show partners for joining us to help you make your low tox swaps! Weleda - a global leader in natural science and beauty, gives you 20% off sitewide in April. Code LOWTOXLIFE. Stock up on favourites or make your swaps and experience the power of nature for your skin (our faves are the shower bars, rose face care range, arnica EVERYTHING, rosemary hair tonic, deep cleansing gel - Oh, and Calendula range for the bubs!) Enjoy!@ausclimate giving you 10% off their range for the whole of 2025, with brilliant Winix Air Purifiers, the best Dehumidifiers I've ever used and their new energy-efficient heating, air-circulating and cooling range. code LOWTOXLIFE (also works over and above their sales - pro tip!) https://bit.ly/ShopAusclimateBe sure to join me on Instagram @lowtoxlife and tag me with your shares and AHAs if something resonated! I would love to see your thoughts! Want to support the Low Tox Life podcast? Free option: Leave a 5 star review wherever you listen to Low Tox Life - thanks SO much! Paid + Member PERKS: Join the Low Tox Club - monthly practitioner live masterclasses, a suite of low tox store discounts from around the world and the most supportive and lovely chat group on all low tox topics on the internet: Check it out and join here for just the price of a coffee per month! Hosted on Acast. See acast.com/privacy for more information.

With the major indices aiming for a third consecutive day of gains, Carl Quintanilla, Jim Cramer and David Faber reacted to a new survey that shows investors haven't been this bearish about growth in 30 years. Tariffs and the trade war also in the spotlight: President Trump setting the stage for tariffs on chips and pharmaceuticals, China reportedly orders its airlines not to accept deliveries of Boeing jets. Also in focus: Bank of America and Citi post earnings beats, what Johnson & Johnson's CFO told CNBC about pharma tariffs, Netflix's $1 trillion goal, luxury pain for LVMH, activism lifts HPE shares. Squawk on the Street Disclaimer

In this week's MBA Admissions podcast we began by discussing the Round 3 activity on LiveWire; interview invites are now starting to roll out for this shortened application round. Graham then announced the recent partnership Clear Admit has now established with Leland, which will now become our partner for MBA admissions coaching, test prep, and career counseling. Graham noted Clear Admit's Application Overview May series of events. These online events will be hosted on May 6 and 7, and May 20 and 21. Signups are here: https://bit.ly/appoverview25 Sandwiched in the middle of these events is Clear Admit's MBA admissions fair in Boston, on May 14th. Twenty-four of the top 25 U.S.-based MBA programs are planning to attend, along with London Business School. Signups for this event are here: https://bit.ly/mbafair2025 Graham noted a Clear Admit admissions tip focused on what candidates need to do, if they were not able to secure admissions at the targeted MBA programs. Graham then highlighted two recent articles from Clear Admit that focus on NYU / Stern's new dean, and UPenn / Wharton's new AI major. We then discussed the recent publication of 2025 US News's rankings, which led to a discussion on their overall methodology. Graham highlighted four Real Humans alumni spotlights, alums from IMD working at Johnson & Johnson, Cornell / Johnson working at Elephant Energy, Vanderbilt / Owen working at Amazon, and London Business School working as an entrepreneur. For this week, for the candidate profile review portion of the show, Alex selected one ApplyWire entry and two DecisionWire entries: This week's first MBA admissions candidate is clearly non-traditional; for that reason, we discussed some of the approaches that non-traditional candidates need to pursue, including a strong focus on “why MBA” and their goals. This week's second MBA candidate is choosing between Berkeley / Haas and Northwestern / Kellogg's MBAi. They want to do product management in tech, in Texas. The final MBA candidate is choosing between UVA / Darden and NYU / Stern. They have a full-ride scholarship at both and want to purse MBB consulting. This episode was recorded in Atlanta, Georgia and Cornwall, England. It was produced and engineered by the fabulous Dennis Crowley in Philadelphia, USA. Thanks to all of you who've been joining us and please remember to rate and review this show wherever you listen!

An interview with investigative journalist Gardiner Harris regarding his newly released exposé No More Tears that unpacks Johnson & Johnson's white collar criminality, murderous corporate malfeasance, and myriad coverup conspiracies that have left millions dead.Support the show by subscribing to the PPM Patreon and gain access to a bonus, solo ep that explores Gardiner's father's fascinating career as a bureau chief at Time Inc. and protege of spooky, anticommunist publisher Henry Luce (a mini-primer on Luce's myriad ties to intelligence, Cuban paramilitaries, Gladio via his wife Clare Boothe Luce, and the JFK assassination):patreon.com/ParaPowerMapping***One day in 2004, Gardiner Harris, a pharmaceutical reporter for The New York Times, was early for a flight and sat down at an airport bar. He struck up a conversation with the woman on the barstool next to him, who happened to be a drug sales rep for Johnson & Johnson. Her horrific story about unethical sales practices and the devastating impact they'd had on her family fundamentally changed the nature of how Harris would cover the company—and the entire pharmaceutical industry. His subsequent investigations and ongoing research since that very first conversation led to this book—a blistering exposé of a trusted American institution and the largest healthcare conglomerate in the world.Harris takes us light-years away from the company's image as the child-friendly “baby company” as he uncovers reams of evidence showing decades of deceitful and dangerous corporate practices that have threatened the lives of millions. He covers multiple disasters: lies and cover-ups regarding the link of Johnson's Baby Powder to cancer, the surprising dangers of Tylenol, a criminal campaign to sell antipsychotics that have cost countless lives, a popular drug used to support cancer patients that actually increases the risk that cancer tumors will grow, and deceptive marketing that accelerated opioid addictions through their product Duragesic (fentanyl) that rival even those of the Sacklers and Purdue Pharma.Filled with shocking and infuriating but utterly necessary revelations, No More Tears is a landmark work of investigative journalism that lays bare the deeply rooted corruption behind the image of babies bathing with a smile.***Songs:| The Chemical Brothers - "The Pills Won't Help You Now" || Spiritualized - "Medication" |

Market Match from the Ecology Center Website On today's show, I'll speak to Stacy Malkan, US Right To Know co-founder and managing editor, about Bayer/Monsanto's latest scheme to get out paying billions in compensation for all the cancer it has knowlingly caused.  We'll switch gears and speak to Ecology Center's executive director Martin Bourque about the possible federal cuts to SNAP/EBT. Stacy Malkan's report on Johnson & Johnson talcum powder scandal and settlement: Johnson & Johnson talc baby powder asbestos trials: key facts   The post Roundup Lawsuits & SNAP Cuts appeared first on KPFA.

Johnson & Johnson recently lost a bid to settle lawsuits that claimed its talc powder products, including baby powder, caused cancer. Author Gardiner Harris says the company's defense "is beginning to crumble." His book is No More Tears. Also, John Powers reviews the new Apple TV+ series Your Friends & Neighbors, starring Jon Hamm.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

This episode covers: Cardiology This Week: A concise summary of recent studies Current indications for pulmonary vein isolation Conduction system pacing EHRA 2025 scientific highlights Host: Susanna Price Guests: Haran Burri, Isabel Deisenhofer, Helmut Puererfellner, Emma Svennberg Want to watch that episode? Go to: https://esc365.escardio.org/event/1803   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Haran Burri has declared to have potential conflicts of interest to report: institutional research and fellowship support or speaker honoraria from Abbott, Biotronik, Boston Scientific, Medtronic, Microport. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Isabel Deisenhofer has declared to have potential conflicts of interest to report: speaker honoraria and travel grants from Abbott Medical, Biosense-Webster, Boston Scientific, BMS, Volta Medical, and research grant (for the institution) from Abbott Medical and Daiichi Sankyo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Helmut Puererfellner has declared to have potential conflicts of interest to report: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities for the following companies: Abbott, Biotronik, Biosense Webster, Boston Scientific, Daiichi Sankyo, Medtronic. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Dal Perio is a Senior Manager of Sensory & Product Insights at Starbucks, with 30 years of experience in Sensory Science, Consumer Research, and Marketing Research across seven Fortune 500 companies including Johnson & Johnson, Diageo, and Unilever.   His expertise spans Product Innovation, Consumer Research, Quality Assurance, and Product Testing. At Starbucks, he focuses on Sensory & Product Insights for various channels, ensuring optimal research solutions. He's actively involved in numerous professional sensory organizations and was mentored by Rose Marie Pangborn.   To be put in touch with Dal, please contact Aigora. To learn more about Aigora, please visit www.aigora.com

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD information, and to apply for credit, please visit us at PeerView.com/JFE865. CME/MOC/NCPD credit will be available until April 18, 2026.Unlocking Efficacy, Expanding Access to CAR-T in Lymphoma and Myeloma: From Practice-Changing Evidence to Real-World and Outpatient Experiences In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies), Legend Biotech, and Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.

How can you take a human-first approach to skills-based learning? Why should you have a clear business case before implementing skills-based talent initiatives?My guest on this episode is Christina Norris-Watts, Head of Assessment & People Practices at Johnson & JohnsonDuring our conversation Christina and I discuss:Why Christina says transitioning to a skills-based organization is like eating your brussels sprouts.The strategic approach Johnson & Johnson took to implement skills-based talent initiatives across the organization.How the J&J Credo shaped their distinctive “human-first” strategy for creating personalized learning and development paths.The way J&J's innovative learning platform successfully integrates the three E's: Experience, Exposure, and Education.Advice for HR leaders beginning their skills journey including where to start and challenges to avoid. Connecting with Christina: Connect with Christina Norris-Watts on LinkedInEpisode Sponsor: Next-Gen HR Accelerator - Learn more about this best-in-class leadership development program for next-gen HR leadersElevate 2025 - Learn more about this once a year, 3-week virtual program focused on taking your strategic capabilities and business impact to the next level with 16 interactive sessions led by 18 HR thought leaders.HR Leader's Blueprint - 18 pages of real-world advice from 100+ HR thought leaders. Simple, actionable, and proven strategies to advance your career.Succession Planning Playbook: In this focused 1-page resource, I cut through the noise to give you the vital elements that define what “great” succession planning looks like.

The reconciliation bill remains stalled in Congress. Senator Bill Cassidy (R- Louisiana) says the government must first reel in its “out-of-control” spending and debt to defend the American Dream. John Hope Bryant weighs in on why he believes financial literacy needs to be taught to every American at every education level. Plus, OpenAI closes a funding round at $40 billion, the largest private tech deal on record, Johnson & Johnson loses in court again in its bid to settle talc cases and shares of Newsmax surge for a second day after a massive IPO debut on Monday. Sen. Bill Cassidy - 16:57Kate Rooney - 28:22John Hope Bryant - 30:33 In this episode:Becky Quick, @BeckyQuickJoe Kernen, @JoeSquawkAndrew Ross Sorkin, @andrewrsorkinKatie Kramer, @Kramer_KatieBill Cassidy, @SenBillCassidyJohn Hope Bryant, @johnhopebryantKate Rooney, @Kr00ney

After the worst quarter for stocks since 2022, Carl Quintanilla, Jim Cramer and David Faber explored how investors should navigate the markets in Q2 – especially in light of President Trump's reciprocal tariff announcement slated for Wednesday. The "Magnificent 7" in focus after their rough Q1: Cramer sounds off after posting on social media about the "savage attack on NVDA by the bears." Also in focus: A federal bankruptcy judge rejects Johnson & Johnson's talc lawsuit settlement proposal, "buy" calls on Apple, actor Walton Goggins of HBO's "The White Lotus" joined the anchors at Post 9 in a surprise appearance. Squawk on the Street Disclaimer

  S&P 500 Bounce? After a rough start, Monday's trading saw a small recovery. But with Trump's "Liberation Day" tariff announcements looming, markets could be in for more volatility. Budget Vote Approaches: The ANC lacks votes to pass the postponed budget, with opposition parties like MK and EFF holding out. Political and economic uncertainty remains high. Commodities on a Quiet Rally: Gold (+19.5%), Copper (+26.5%), and Rhodium (+24.5%) lead the way, while oil and aluminium lag. The CRB Index is up 5.4% year-to-date. Atlanta Fed GDP Now Update: Q1 GDP estimate revised to -0.5% from -2.8%. Adjustments for gold trade data make the outlook slightly less dire. Amazon at a Discount? Stock down 20% from its highs, with a historically low P/E ratio of 34. Analysts see upside potential. Amazon | Weekly Chat | 31 March 2025 Johnson & Johnson's Dividend Appeal: Trading near $165, with a potential drop to $150 making its 3% yield even more attractive. Johnson & Johnson | Weekly Chat | 31 March 2025 New ETNs on the JSE: Nvidia, Palantir, Novo Nordisk, and more available via FNB, offering exposure to top global stocks with local accessibility. Simon Brown * I hold ungeared positions. All charts by KoyFin | Get 10% off your order 00:00 Market Overview and Economic Indicators 03:09 US Tariff Implications and Market Reactions 05:45 Commodities Performance and Economic Impact 09:03 Stock Analysis: Amazon's Market Position 12:00 Stock Analysis: Johnson & Johnson's Stability 14:38 Investment Strategies and Innovations  

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he breaks down today's biggest stories shaping America and the world. Trump Slaps 25% Tariffs on All Foreign Cars – As part of his broader push to reindustrialize America, the president announces new auto tariffs and hints at a sweeping global trade overhaul launching April 2nd. Foreign automakers and countries are already scrambling to respond. Are the Tariffs Working? Early Data Says Yes – Major companies like Hyundai, Johnson & Johnson, and Canadian manufacturers are expanding U.S. operations. Meanwhile, Vietnam rushes to cut its own tariffs and curry favor with Washington. Americans Still Anxious About the Economy – Despite strong reshoring trends, uneven price effects, political divisions, and media narratives are fueling economic confusion—especially among Democrats, who report much lower consumer confidence. Trump Scores a Series of Domestic Wins, Angering the Left – From tighter border control and collapsing sanctuary state budgets, to cutting university funding and reining in partisan law firms, Trump's aggressive moves are reshaping America—and sparking outrage across Democratic strongholds. Is Partisanship Making Americans Lonely? – New reporting reveals how political polarization—especially among progressive women—may be contributing to a generational decline in marriage and happiness. Get the facts, the analysis, and the truth—only on The Wright Report. "And you shall know the truth, and the truth shall make you free." - John 8:32

With the S&P 500 and Nasdaq snapping four-week losing streaks on Friday, David Faber and Jim Cramer explored Monday's market rally, sparked by reports President Trump will narrow tariffs set to be announced April 2. Tesla among the biggest gainers as the stock looks to avoid a ten-week losing streak. The anchors discussed AI-related developments on the heels of last week's Cramer interview with Nvidia CEO Jensen Huang. Also in focus: Chinese officials court Apple's Tim Cook and other CEOs at a development forum in Beijing, M&A deals, hedge fund pushes for a sale of Johnson & Johnson spin-off Kenvue.  Squawk on the Street Disclaimer